Compare AEMD & VVOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AEMD | VVOS |
|---|---|---|
| Founded | 1984 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.3M | 4.8M |
| IPO Year | 2008 | 2020 |
| Metric | AEMD | VVOS |
|---|---|---|
| Price | $5.86 | $0.14 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 2 | 3 |
| Target Price | ★ $13.25 | $2.12 |
| AVG Volume (30 Days) | ★ 2.4M | 1.6M |
| Earning Date | 11-11-2026 | 11-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 6.76 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $17,443,000.00 |
| Revenue This Year | N/A | $24.92 |
| Revenue Next Year | N/A | $56.44 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 16.05 |
| 52 Week Low | $0.53 | $0.13 |
| 52 Week High | $35.97 | $3.28 |
| Indicator | AEMD | VVOS |
|---|---|---|
| Relative Strength Index (RSI) | 58.98 | 32.21 |
| Support Level | $3.20 | $0.13 |
| Resistance Level | $6.69 | $0.55 |
| Average True Range (ATR) | 0.34 | 0.01 |
| MACD | -0.14 | 0.01 |
| Stochastic Oscillator | 0.89 | 40.19 |
Aethlon Medical Inc is a medical therapeutic company focused on developing the Hemopurifier (HP), a clinical-stage investigational immunotherapeutic device designed to address unmet needs in oncology, life-threatening infectious diseases, organ transplantation and other disease states in which extracellular vesicles (EVs) contribute to disease progression. The Hemopurifier utilizes a proprietary lectin-based technology to bind and remove enveloped viruses and EVs from biological fluids. EVs have been associated with immune suppression, metastasis, and resistance to therapy in cancer, as well as progression of severe infectious diseases. The Company operates as a single reportable segment.
Vivos Therapeutics Inc is a medical technology company. It is focused on the development and commercialization of a technology offering non-surgical, non-invasive, non-pharmaceutical, and low-cost solution for patients with sleep-disordered breathing (SDB), including mild-to-moderate obstructive sleep apnea (OSA). The company provides treatment for mild-to-moderate OSA involves customized oral appliances and protocols called the Vivos System. The Vivos systme is an therapeutic protocol, which often combines the use of customized oral appliance specifications and proprietary clinical treatments developed by company and prescribed by specially trained dentists in cooperation with their medical colleagues.